Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-blind, Randomized, Controlled, Multicentre Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, gE/AS01B, and to Compare 3 Doses of gE With AS01B Adjuvant in Healthy Elderly Subjects, Aged 60 to 69 Years and 70 Years and Above.

NCT00434577 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00434577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00434577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-blind, Randomized, Controlled, Multicentre Vaccination Study to Evaluate the Safety and Immune Response of the GSK Biologicals Zoster Vaccine, gE/AS01B, and to Compare 3 Doses of gE With AS01B Adjuvant in Healthy Elderly Subjects, Aged 60 to 69 Years and 70 Years and Above.
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
February 14, 2007
Completion date
July 14, 2010
Enrollment
715 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster